Quoin Change In Cash vs Cash Flow To Debt Ratio Analysis

QNRX Stock

USD 0.59 0.03 4.84%

Quoin Pharmaceuticals financial indicator trend analysis is much more than just breaking down Quoin Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Quoin Pharmaceuticals is a good investment. Please check the relationship between Quoin Pharmaceuticals Change In Cash and its Cash Flow To Debt Ratio accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Quoin Pharmaceuticals Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Change In Cash vs Cash Flow To Debt Ratio

Change In Cash vs Cash Flow To Debt Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Quoin Pharmaceuticals Change In Cash account and Cash Flow To Debt Ratio. At this time, the significance of the direction appears to have very week relationship.

The correlation between Quoin Pharmaceuticals' Change In Cash and Cash Flow To Debt Ratio is 0.29. Overlapping area represents the amount of variation of Change In Cash that can explain the historical movement of Cash Flow To Debt Ratio in the same time period over historical financial statements of Quoin Pharmaceuticals Ltd, assuming nothing else is changed. The correlation between historical values of Quoin Pharmaceuticals' Change In Cash and Cash Flow To Debt Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change In Cash of Quoin Pharmaceuticals Ltd are associated (or correlated) with its Cash Flow To Debt Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash Flow To Debt Ratio has no effect on the direction of Change In Cash i.e., Quoin Pharmaceuticals' Change In Cash and Cash Flow To Debt Ratio go up and down completely randomly.

Correlation Coefficient

0.29

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Change In Cash

Cash Flow To Debt Ratio

Most indicators from Quoin Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Quoin Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Quoin Pharmaceuticals Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Selling General Administrative is likely to drop to about 4 M in 2024. Sales General And Administrative To Revenue is likely to drop to -26.89 in 2024

	2023	2024 (projected)
Reconciled Depreciation	119.6K	96.1K
Cost Of Revenue	103.4K	102.9K

Reconciled Depreciation Cost Of Revenue

Quoin Pharmaceuticals fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Current Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Net Tangible Assets	Current Deferred Revenue	Retained Earnings	Accounts Payable	Non Currrent Assets Other	Net Receivables	Non Current Liabilities Total	Inventory	Other Current Assets	Total Liab	Short Term Debt	Intangible Assets
Total Assets		0.92	0.23	-0.1	0.72	0.68	0.81	0.59	0.22	0.34	0.56	-0.09	0.08	-0.28	0.05	0.31	-0.23	-0.02	0.33	0.01	-0.09	0.01	-0.06	-0.22	-0.09	0.06
Total Stockholder Equity	0.92		-0.12	-0.27	0.51	0.4	0.9	0.33	0.47	0.18	0.3	-0.26	0.25	-0.58	-0.1	0.57	-0.27	-0.24	0.46	0.08	-0.26	0.08	-0.3	-0.52	-0.26	0.27
Property Plant And Equipment Net	0.23	-0.12		0.35	0.32	0.76	-0.22	0.68	-0.78	0.69	0.7	0.35	-0.35	0.73	0.6	-0.51	-0.12	0.68	-0.17	-0.3	0.35	-0.3	0.76	0.84	0.35	-0.75
Net Debt	-0.1	-0.27	0.35		0.3	0.09	-0.24	0.14	-0.33	0.17	0.18	1.0	-1.0	0.63	0.13	-0.69	0.08	0.7	0.05	0.1	1.0	0.1	0.61	0.5	1.0	-0.2
Cash	0.72	0.51	0.32	0.3		0.69	0.39	0.69	-0.05	0.32	0.68	0.31	-0.31	0.03	0.03	-0.04	-0.11	0.2	0.23	0.01	0.31	0.01	0.13	0.0	0.31	0.01
Non Current Assets Total	0.68	0.4	0.76	0.09	0.69		0.25	0.78	-0.52	0.62	0.78	0.1	-0.1	0.36	0.39	-0.17	-0.15	0.35	-0.02	-0.27	0.1	-0.27	0.38	0.44	0.1	-0.42
Other Assets	0.81	0.9	-0.22	-0.24	0.39	0.25		0.01	0.63	-0.17	-0.02	-0.23	0.23	-0.53	-0.44	0.34	0.12	-0.47	0.1	0.31	-0.23	0.31	-0.52	-0.59	-0.23	0.53
Cash And Short Term Investments	0.59	0.33	0.68	0.14	0.69	0.78	0.01		-0.45	0.82	1.0	0.15	-0.15	0.19	0.66	0.1	-0.54	0.59	0.44	-0.32	0.15	-0.32	0.59	0.39	0.15	-0.6
Common Stock Shares Outstanding	0.22	0.47	-0.78	-0.33	-0.05	-0.52	0.63	-0.45		-0.66	-0.49	-0.33	0.32	-0.76	-0.65	0.48	0.19	-0.67	0.14	0.45	-0.33	0.45	-0.75	-0.85	-0.33	0.77
Other Stockholder Equity	0.34	0.18	0.69	0.17	0.32	0.62	-0.17	0.82	-0.66		0.84	0.17	-0.17	0.23	0.82	0.12	-0.68	0.71	0.51	-0.43	0.18	-0.43	0.74	0.48	0.17	-0.77
Total Current Assets	0.56	0.3	0.7	0.18	0.68	0.78	-0.02	1.0	-0.49	0.84		0.19	-0.19	0.23	0.69	0.07	-0.54	0.63	0.43	-0.33	0.19	-0.33	0.63	0.43	0.19	-0.63
Short Long Term Debt Total	-0.09	-0.26	0.35	1.0	0.31	0.1	-0.23	0.15	-0.33	0.17	0.19		-1.0	0.63	0.13	-0.68	0.08	0.7	0.06	0.1	1.0	0.1	0.6	0.5	1.0	-0.2
Other Current Liab	0.08	0.25	-0.35	-1.0	-0.31	-0.1	0.23	-0.15	0.32	-0.17	-0.19	-1.0		-0.62	-0.13	0.68	-0.07	-0.7	-0.06	-0.1	-1.0	-0.1	-0.6	-0.49	-1.0	0.2
Total Current Liabilities	-0.28	-0.58	0.73	0.63	0.03	0.36	-0.53	0.19	-0.76	0.23	0.23	0.63	-0.62		0.4	-0.86	0.14	0.67	-0.42	-0.31	0.63	-0.31	0.72	0.94	0.63	-0.6
Net Tangible Assets	0.05	-0.1	0.6	0.13	0.03	0.39	-0.44	0.66	-0.65	0.82	0.69	0.13	-0.13	0.4		0.08	-0.79	0.78	0.47	-0.74	0.13	-0.74	0.84	0.66	0.13	-0.96
Current Deferred Revenue	0.31	0.57	-0.51	-0.69	-0.04	-0.17	0.34	0.1	0.48	0.12	0.07	-0.68	0.68	-0.86	0.08		-0.58	-0.37	0.67	-0.14	-0.68	-0.14	-0.39	-0.68	-0.68	0.16
Retained Earnings	-0.23	-0.27	-0.12	0.08	-0.11	-0.15	0.12	-0.54	0.19	-0.68	-0.54	0.08	-0.07	0.14	-0.79	-0.58		-0.48	-0.85	0.7	0.07	0.7	-0.48	-0.1	0.08	0.62
Accounts Payable	-0.02	-0.24	0.68	0.7	0.2	0.35	-0.47	0.59	-0.67	0.71	0.63	0.7	-0.7	0.67	0.78	-0.37	-0.48		0.35	-0.38	0.7	-0.38	0.98	0.79	0.7	-0.8
Non Currrent Assets Other	0.33	0.46	-0.17	0.05	0.23	-0.02	0.1	0.44	0.14	0.51	0.43	0.06	-0.06	-0.42	0.47	0.67	-0.85	0.35		-0.26	0.06	-0.26	0.26	-0.23	0.06	-0.22
Net Receivables	0.01	0.08	-0.3	0.1	0.01	-0.27	0.31	-0.32	0.45	-0.43	-0.33	0.1	-0.1	-0.31	-0.74	-0.14	0.7	-0.38	-0.26		0.1	1.0	-0.48	-0.43	0.1	0.73
Non Current Liabilities Total	-0.09	-0.26	0.35	1.0	0.31	0.1	-0.23	0.15	-0.33	0.18	0.19	1.0	-1.0	0.63	0.13	-0.68	0.07	0.7	0.06	0.1		0.1	0.6	0.5	1.0	-0.2
Inventory	0.01	0.08	-0.3	0.1	0.01	-0.27	0.31	-0.32	0.45	-0.43	-0.33	0.1	-0.1	-0.31	-0.74	-0.14	0.7	-0.38	-0.26	1.0	0.1		-0.48	-0.43	0.1	0.73
Other Current Assets	-0.06	-0.3	0.76	0.61	0.13	0.38	-0.52	0.59	-0.75	0.74	0.63	0.6	-0.6	0.72	0.84	-0.39	-0.48	0.98	0.26	-0.48	0.6	-0.48		0.86	0.6	-0.89
Total Liab	-0.22	-0.52	0.84	0.5	0.0	0.44	-0.59	0.39	-0.85	0.48	0.43	0.5	-0.49	0.94	0.66	-0.68	-0.1	0.79	-0.23	-0.43	0.5	-0.43	0.86		0.5	-0.82
Short Term Debt	-0.09	-0.26	0.35	1.0	0.31	0.1	-0.23	0.15	-0.33	0.17	0.19	1.0	-1.0	0.63	0.13	-0.68	0.08	0.7	0.06	0.1	1.0	0.1	0.6	0.5		-0.2
Intangible Assets	0.06	0.27	-0.75	-0.2	0.01	-0.42	0.53	-0.6	0.77	-0.77	-0.63	-0.2	0.2	-0.6	-0.96	0.16	0.62	-0.8	-0.22	0.73	-0.2	0.73	-0.89	-0.82	-0.2

Click cells to compare fundamentals

Quoin Pharmaceuticals Account Relationship Matchups

Quoin Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	6.2M	1.4M	9.4M	14.5M	12.2M	11.7M
Total Stockholder Equity	4.3M	(6.6M)	657.0K	7.4M	5.7M	6.6M
Property Plant And Equipment Net	1.4M	1.3M	672.6K	1.9M	2.2M	1.3M
Net Debt	(4.9M)	889.5K	736.4M	(2.9M)	(2.4M)	(2.3M)
Cash	5.2M	323.8K	7.5M	2.9M	2.4M	4.0M
Non Current Assets Total	794.7K	912.6K	858.6K	1.1M	883.3K	1.0M
Other Assets	15.3M	1.0	50K	383.4K	345.1K	327.8K
Cash And Short Term Investments	5.2M	323.8K	7.5M	12.9M	10.7M	8.0M
Common Stock Shares Outstanding	3.5K	20.0K	26.4K	403.9K	900.9K	855.9K
Liabilities And Stockholders Equity	6.2M	1.4M	9.4M	14.5M	12.2M	11.7M
Other Stockholder Equity	28.7M	100.0	28.7M	44.9M	51.9M	28.7M
Total Current Assets	5.4M	465.2K	8.5M	13.4M	11.3M	8.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Quoin Stock Analysis

When running Quoin Pharmaceuticals' price analysis, check to measure Quoin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quoin Pharmaceuticals is operating at the current time. Most of Quoin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Quoin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quoin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Quoin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Quoin Change In Cash vs Cash Flow To Debt Ratio Analysis

Change In Cash vs Cash Flow To Debt Ratio

Change In Cash vs Cash Flow To Debt Ratio Correlation Analysis

Correlation Coefficient

Change In Cash

Cash Flow To Debt Ratio

Quoin Pharmaceuticals fundamental ratios Correlations

Quoin Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Quoin Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for Quoin Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Short Long Term Debt Total	+ 1.0	Net Debt
Non Current Liabilities Total	+ 1.0	Net Debt
Short Term Debt	+ 1.0	Net Debt
Total Current Assets	+ 1.0	Cash And Short Term Investments
Non Current Liabilities Total	+ 1.0	Short Long Term Debt Total
Short Term Debt	+ 1.0	Short Long Term Debt Total

Short Term Debt	- 1.0	Other Current Liab
Non Current Liabilities Total	- 1.0	Other Current Liab
Other Current Liab	- 1.0	Short Long Term Debt Total
Other Current Liab	- 1.0	Net Debt
Intangible Assets	- 0.96	Net Tangible Assets
Intangible Assets	- 0.89	Other Current Assets